Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1887 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ovarian Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively. Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 13 Ovarian Cancer Overview 14 Therapeutics Development 15 Ovarian Cancer - Therapeutics under Development by Companies 17 Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 41 Ovarian Cancer - Pipeline Products Glance 44 Ovarian Cancer - Products under Development by Companies 48 Ovarian Cancer - Products under Investigation by Universities/Institutes 81 Ovarian Cancer - Companies Involved in Therapeutics Development 85 Ovarian Cancer - Therapeutics Assessment 371 Drug Profiles 451 Ovarian Cancer - Dormant Projects 1775 Ovarian Cancer - Discontinued Products 1809 Ovarian Cancer - Product Development Milestones 1816 Appendix 1829
List of Tables
Number of Products under Development for Ovarian Cancer, H2 2016 72 Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016 73 Number of Products under Development by Companies, H2 2016 75 Number of Products under Development by Companies, H2 2016 (Contd..1) 76 Number of Products under Development by Companies, H2 2016 (Contd..2) 77 Number of Products under Development by Companies, H2 2016 (Contd..3) 78 Number of Products under Development by Companies, H2 2016 (Contd..4) 79 Number of Products under Development by Companies, H2 2016 (Contd..5) 80 Number of Products under Development by Companies, H2 2016 (Contd..6) 81 Number of Products under Development by Companies, H2 2016 (Contd..7) 82 Number of Products under Development by Companies, H2 2016 (Contd..8) 83 Number of Products under Development by Companies, H2 2016 (Contd..9) 84 Number of Products under Development by Companies, H2 2016 (Contd..10) 85 Number of Products under Development by Companies, H2 2016 (Contd..11) 86 Number of Products under Development by Companies, H2 2016 (Contd..12) 87 Number of Products under Development by Companies, H2 2016 (Contd..13) 88 Number of Products under Development by Companies, H2 2016 (Contd..14) 89 Number of Products under Development by Companies, H2 2016 (Contd..15) 90 Number of Products under Development by Companies, H2 2016 (Contd..16) 91 Number of Products under Development by Companies, H2 2016 (Contd..17) 92 Number of Products under Development by Companies, H2 2016 (Contd..18) 93 Number of Products under Development by Companies, H2 2016 (Contd..19) 94 Number of Products under Development by Companies, H2 2016 (Contd..20) 95 Number of Products under Development by Companies, H2 2016 (Contd..21) 96 Number of Products under Development by Companies, H2 2016 (Contd..22) 97 Number of Products under Investigation by Universities/Institutes, H2 2016 98 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 99 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 100 Comparative Analysis by Late Stage Development, H2 2016 101 Comparative Analysis by Clinical Stage Development, H2 2016 102 Comparative Analysis by Early Stage Development, H2 2016 103 Comparative Analysis by Unknown Stage Development, H2 2016 104 Products under Development by Companies, H2 2016 105 Products under Development by Companies, H2 2016 (Contd..1) 106 Products under Development by Companies, H2 2016 (Contd..2) 107 Products under Development by Companies, H2 2016 (Contd..3) 108 Products under Development by Companies, H2 2016 (Contd..4) 109 Products under Development by Companies, H2 2016 (Contd..5) 110 Products under Development by Companies, H2 2016 (Contd..6) 111 Products under Development by Companies, H2 2016 (Contd..7) 112 Products under Development by Companies, H2 2016 (Contd..8) 113 Products under Development by Companies, H2 2016 (Contd..9) 114 Products under Development by Companies, H2 2016 (Contd..10) 115 Products under Development by Companies, H2 2016 (Contd..11) 116 Products under Development by Companies, H2 2016 (Contd..12) 117 Products under Development by Companies, H2 2016 (Contd..13) 118 Products under Development by Companies, H2 2016 (Contd..14) 119 Products under Development by Companies, H2 2016 (Contd..15) 120 Products under Development by Companies, H2 2016 (Contd..16) 121 Products under Development by Companies, H2 2016 (Contd..17) 122 Products under Development by Companies, H2 2016 (Contd..18) 123 Products under Development by Companies, H2 2016 (Contd..19) 124 Products under Development by Companies, H2 2016 (Contd..20) 125 Products under Development by Companies, H2 2016 (Contd..21) 126 Products under Development by Companies, H2 2016 (Contd..22) 127 Products under Development by Companies, H2 2016 (Contd..23) 128 Products under Development by Companies, H2 2016 (Contd..24) 129 Products under Development by Companies, H2 2016 (Contd..25) 130 Products under Development by Companies, H2 2016 (Contd..26) 131 Products under Development by Companies, H2 2016 (Contd..27) 132 Products under Development by Companies, H2 2016 (Contd..28) 133 Products under Development by Companies, H2 2016 (Contd..29) 134 Products under Development by Companies, H2 2016 (Contd..30) 135 Products under Development by Companies, H2 2016 (Contd..31) 136 Products under Development by Companies, H2 2016 (Contd..32) 137 Products under Investigation by Universities/Institutes, H2 2016 138 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 139 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 140 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 141 Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 142 Ovarian Cancer - Pipeline by 4SC AG, H2 2016 143 Ovarian Cancer - Pipeline by AB Science SA, H2 2016 144 Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016 145 Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2016 146 Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 147 Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 148 Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 149 Ovarian Cancer - Pipeline by Aduro BioTech Inc, H2 2016 150 Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 151 Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 152 Ovarian Cancer - Pipeline by Advaxis Inc, H2 2016 153 Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 154 Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 155 Ovarian Cancer - Pipeline by Alchemia Ltd, H2 2016 156 Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 157 Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2016 158 Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2016 159 Ovarian Cancer - Pipeline by Alteogen Inc, H2 2016 160 Ovarian Cancer - Pipeline by Ambrx Inc, H2 2016 161 Ovarian Cancer - Pipeline by Amgen Inc, H2 2016 162 Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 163 Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2016 164 Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2016 165 Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2016 166 Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 167 Ovarian Cancer - Pipeline by Aphios Corp, H2 2016 168 Ovarian Cancer - Pipeline by Aposense Ltd, H2 2016 169 Ovarian Cancer - Pipeline by Aprea AB, H2 2016 170 Ovarian Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 171 Ovarian Cancer - Pipeline by arGEN-X BV, H2 2016 172 Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 173 Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 174 Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 175 Ovarian Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016 176 Ovarian Cancer - Pipeline by ArQule Inc, H2 2016 177 Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 178 Ovarian Cancer - Pipeline by Arvinas Inc, H2 2016 179 Ovarian Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 180 Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2016 181 Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 182 Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016 183 Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016 184 Ovarian Cancer - Pipeline by Athenex Inc, H2 2016 185 Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 186 Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 187 Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2016 188 Ovarian Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 189 Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 190 Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 191 Ovarian Cancer - Pipeline by Bayer AG, H2 2016 192 Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2016 193 Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 194 Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2016 195 Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2016 196 Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2016 197 Ovarian Cancer - Pipeline by BioNTech AG, H2 2016 198 Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 199 Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 200 Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016 201 Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 202 Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 203 Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 204 Ovarian Cancer - Pipeline by Cavion LLC, H2 2016 205 Ovarian Cancer - Pipeline by Cellceutix Corp, H2 2016 206 Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 207 Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 208 Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 209 Ovarian Cancer - Pipeline by Celon Pharma SA, H2 2016 210 Ovarian Cancer - Pipeline by Celprogen Inc, H2 2016 211 Ovarian Cancer - Pipeline by Celsion Corp, H2 2016 212 Ovarian Cancer - Pipeline by Celyad SA, H2 2016 213 Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2016 214 Ovarian Cancer - Pipeline by CerRx Inc, H2 2016 215 Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 216 Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 217 Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016 218 Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016 219 Ovarian Cancer - Pipeline by CohBar Inc, H2 2016 220 Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 221 Ovarian Cancer - Pipeline by Commence Bio Inc, H2 2016 222 Ovarian Cancer - Pipeline by Compliment Corp, H2 2016 223
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
